BBOT (BridgeBio Oncology Therapeutics) Total Liabilities: $45.37 Mil (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics Total Liabilities?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 Total Liabilities is $45.37 Mil as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

BridgeBio Oncology Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $45.37 Mil.

BridgeBio Oncology Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($38.09 Mil) to Dec. 2025 ($37.29 Mil) but then increased from Dec. 2025 ($37.29 Mil) to Mar. 2026 ($45.37 Mil).

BridgeBio Oncology Therapeutics's annual Total Liabilities increased from Dec. 2023 ($121.58 Mil) to Dec. 2024 ($342.94 Mil) but then declined from Dec. 2024 ($342.94 Mil) to Dec. 2025 ($37.29 Mil).

BridgeBio Oncology Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Total Liabilities Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
121.58 342.94 37.29

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 349.87 378.99 38.09 37.29 45.37
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BridgeBio Oncology Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.041+(2.244+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=37.29

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=448.381-411.096
=37.29

BridgeBio Oncology Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.26+(2.106+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=45.37

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=417.646-372.28
=45.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $45.37 Mil mean?
BridgeBio Oncology Therapeutics (BBOT) has a Total Liabilities of $45.37 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Total Liabilities too high?
BridgeBio Oncology Therapeutics' current Total Liabilities is $45.37 Mil. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Total Liabilities compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Total Liabilities of $45.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Total Liabilities is $45.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Total Liabilities of $45.37 Mil. The current Total Liabilities is $45.37 Mil. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Total Liabilities is $45.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price